Full Papers
Radiographic vertebral fractures develop in patients with ankylosing spondylitis during 4 years of TNF-α blocking therapy
F. Maas1, A. Spoorenberg2, E. Brouwer3, A.M. Schilder4, R.N. Chaudhry5, F. Wink6, H. Bootsma7, E. Van Der Veer8, S. Arends9
- Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, The Netherlands. f.maas@umcg.nl
- Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen; and Department of Rheumatology, Medical Center Leeuwarden, The Netherlands.
- Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, The Netherlands.
- Department of Rheumatology, Medical Center Leeuwarden, The Netherlands.
- Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, The Netherlands.
- Department of Rheumatology, Medical Center Leeuwarden, The Netherlands.
- Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, The Netherlands.
- Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen, The Netherlands.
- Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen; and Department of Rheumatology, Medical Center Leeuwarden, The Netherlands.
CER8295
2016 Vol.34, N°2
PI 0191, PF 0199
Full Papers
Free to view
(click on article PDF icon to read the article)
PMID: 26886385 [PubMed]
Received: 16/01/2015
Accepted : 04/05/2015
In Press: 09/02/2016
Published: 13/04/2016
Abstract
OBJECTIVES:
To determine the prevalence and incidence of radiographic vertebral fractures in ankylosing spondylitis (AS) patients treated with TNF-α blocking therapy for 4 years and to explore the relationship with patient characteristics, clinical assessments, radiographic damage, and bone mineral density (BMD).
METHODS:
This study included consecutive AS patients with active disease from the Groningen Leeuwarden AS (GLAS) cohort treated with TNF-α blocking therapy for 4 years and with available thoracic and lumbar radiographs at baseline and at 4 years. Vertebral fractures were assessed by two readers (mild: ≥20-<25%, moderate: ≥25-<40%, severe: ≥40% reduction in vertebral height).
RESULTS:
In 27 of 105 (26%) AS patients, radiographic vertebral fractures were observed at baseline. These patients were significantly older, had larger occiput-to-wall distance, and more spinal radiographic damage. During 4 years of TNF-α blocking therapy, 21 (20%) patients developed at least one new fracture. Older age, smoking, higher BASFI, low lumbar spine BMD (Z-score ≤-2), presence of moderate vertebral fractures, and use of anti-osteoporotic treatment at baseline were associated with the development of new fractures. Most fractures were mild and occurred in the thoracic spine. The improvement in lateral spinal mobility and lumbar spine BMD during treatment was significantly less in patients with new fractures (median change of 0.8 vs. 2.8 cm and 0.3 vs. 0.8 Z-score, respectively).
CONCLUSIONS:
The prevalence of radiographic vertebral fractures was high in AS patients with active disease. Although clinical assessments and BMD improved significantly, new vertebral fractures still developed during 4 years of TNF-α blocking therapy.
